Vanda Pinto, PhD, science writer —

​​Vanda is a biochemist with a PhD in biomedicine from the University of Porto, Portugal. She conducted her postdoctoral research first at the Bristol Medical School, U.K., studying the insulin-PI3K/Akt signaling pathway in diabetic nephropathy, then at the Institute of Molecular Pathology and Immunology of the University of Porto, where her focus was on glycosylation in lupus nephritis and inflammatory bowel disease. She next made the switch to science publishing, handling papers in biochemistry, molecular biology, and immunology.

Articles by Vanda Pinto

Upstaza, Gene Therapy for AADC Deficiency, Approved in UK

The gene therapy Upstaza (eladocagene exuparvovec) has been approved in the U.K. to treat adults and children, 18 months and older, with aromatic l-amino acid decarboxylase (AADC) deficiency. This decision by the country’s Medicines and Healthcare Products Regulatory Agency (MHRA) comes about four months after a similar approval by…

Global Genes Seeks Applications for 2022 RARE Meet-Ups Grants

Global Genes, a worldwide non-profit, is seeking to support in-person meet-ups that provide access to educational resources and assistance for patients, caregivers, and advocates for rare diseases, such as aromatic l-amino acid decarboxylase (AADC) deficiency. Under the group’s 2022 RARE Meet-Ups Impact Grant program, U.S.-based support groups…